Dr Lam is a Professor at Duke-National University of Singapore and Senior Consultant at the National Heart Centre Singapore specializing in heart failure and recognized globally for expertise in heart failure with preserved ejection fraction. She is a world-renown clinical trialist, with her work as part of the global steering committee of the PARAGON and EMPEROR-Preserved trials contributing to the first FDA-approved treatment for HFpEF (Entresto Wins First FDA Nod in Hard-to-Treat Type of Heart Failure (ajmc.com)) as well as the first robustly positive outcomes trial in HFpEF to date. Her leadership in the field is recognized in her appointment to the 2021 European Society of Cardiology Heart Failure Guidelines Task Force. She is a recipient of the NMRC Senior Investigator Clinician Scientist Award, Chief of Clinical Research in Asia Pacific and Chief of Innovation in Artificial Intelligence at the Baim Institute, Programme Lead of A*STaRs Asian neTwork for Translational Research and Cardiovascular Trials (ATTRaCT), Principal Investigator of ASIAN-HF (multinational study across 11 Asian countries), and Executive Committee member/ lead of multiple global clinical trials. She has published >560 articles in journals including NEJM, JAMA, Lancet, Circulation, and European Heart Journal; and has been recognized in the Clarivate Highly cited Researcher 2021-2023 (https://www.webofscience.com/wos/author/record/ABD-6810-2021) in the field of Clinical and as a World Expert by Expertscape�s PubMed-based algorithms (top 0.1% of scholars writing about Heart Failure over the past 10 years; Heart Failure: Worldwide - Expertscape.com). She is lead author of the chapter on HFpEF for Braunwald's Heart Disease: A Textbook of Cardiovascular Medicine, 12th Edition and her achievements were recognized in nominations as the European Society of Cardiology (ESC) Rene Laennec Lecturer in Clinical Cardiology in 2022, Heart Failure Society of America (HFSA) 2023 Mihai Gheorghiade Lectureship and Singapore Cardiac Society Lecturer 2024 She serves as Deputy Editor for JACC and JACC: Heart Failure and previously as Associate Editor for Circulation and the European Journal of Heart Failure. In the field of MedTech, Dr. Lam is co-founder of Us2.ai, an award-winning startup dedicated to the automation of the fight against heart disease by applying artificial intelligence to echocardiography (ultrasound of the heart).